Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Bijaya Kumar Padhi
 -- 1523 2023-09-20 15:51:20 |
2 Reference format revised.
Lindsay Dong
 + 7 word(s) 1530 2023-09-22 02:52:15 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Bushi, G.; Padhi, B.K.; Shabil, M.; Satapathy, P.; Rustagi, S.; Pradhan, K.B.; Al-Qaim, Z.H.; Khubchandani, J.; Sah, R.; Sah, S.; et al. Cardiovascular Disease Outcomes Associated with OSA in Diabetics. Encyclopedia. Available online: https://encyclopedia.pub/entry/49436 (accessed on 18 November 2024).
Bushi G, Padhi BK, Shabil M, Satapathy P, Rustagi S, Pradhan KB, et al. Cardiovascular Disease Outcomes Associated with OSA in Diabetics. Encyclopedia. Available at: https://encyclopedia.pub/entry/49436. Accessed November 18, 2024.
Bushi, Ganesh, Bijaya Kumar Padhi, Muhammed Shabil, Prakasini Satapathy, Sarvesh Rustagi, Keerti Bhusan Pradhan, Zahraa Haleem Al-Qaim, Jagdish Khubchandani, Ranjit Sah, Sanjit Sah, et al. "Cardiovascular Disease Outcomes Associated with OSA in Diabetics" Encyclopedia, https://encyclopedia.pub/entry/49436 (accessed November 18, 2024).
Bushi, G., Padhi, B.K., Shabil, M., Satapathy, P., Rustagi, S., Pradhan, K.B., Al-Qaim, Z.H., Khubchandani, J., Sah, R., Sah, S., & Anand, A. (2023, September 20). Cardiovascular Disease Outcomes Associated with OSA in Diabetics. In Encyclopedia. https://encyclopedia.pub/entry/49436
Bushi, Ganesh, et al. "Cardiovascular Disease Outcomes Associated with OSA in Diabetics." Encyclopedia. Web. 20 September, 2023.
Cardiovascular Disease Outcomes Associated with OSA in Diabetics
Edit
This entry is adapted from the peer-reviewed paper 10.3390/diseases11030103

There is significant pathogenic and epidemiological overlap between diabetes and obstructive sleep apnea (OSA).  There may be a possible association between OSA and diabetes and their impact on cardiovascular diseases (CVDs). Identifying and managing OSA in individuals with diabetes at an early phase could potentially reduce the risk of CVDs and its related complications.

sleep apnea cardiovascular diseases diabetes stroke comorbidity

1. Introduction

The global burden of diabetes is increasing, affecting nearly 500 million people in 2017 [1]. By 2025, diabetes is expected to contribute to the death of 1.59 million people globally [1]. One of the major contributors to diabetes-related mortality is cardiovascular disease (CVD) affecting approximately one-third of people with diabetes [2][3]. Though the mortality due to CVDs has decreased over time due to effective secondary prevention strategies, the increasing prevalence of diabetes continues to contribute to the rising burden of CVDs [1][2][4]. OSA is a chronic condition that is increasingly becoming more prevalent. This rise in cases could be attributed to factors such as its potential connection to metabolic syndrome or an increased awareness of the obstructive sleep apnea (OSA) among people, leading to more diagnoses [5][6]. More than 900 million adults have been affected by OSA globally, with about two-fifths in the moderate to severe category [7]. The global prevalence ranges from 9% to 38%, with males (13% to 33%) more likely to be affected than females (6% to 19%) [5]. The elderly and obese individuals are also at higher risk. These latest estimates are higher than those reported in studies from the early 21st century and reflect an increasing prevalence globally [8]. The increased prevalence of OSA is of concern as the risk of obesity, dyslipidemia, diabetes, insomnia, and excessive daytime sleepiness is higher among individuals with OSA [9][10]. Also, OSA can adversely affect the hypoxia–reoxygenation system and sleep cycle, increasing several markers of inflammation, oxidative stress, endothelial dysfunction, and sympathetic activity, thereby increasing the risk of adverse cardiovascular events [11]. Numerous clinical studies have reported elevated levels of inflammatory biomarkers in individuals with OSA. Additionally, researchers have developed animal models of OSA and assessed the changes in biomarkers. Several of these experiments have provided evidence that intermittent hypoxia can activate inflammatory pathways, potentially leading to the development of cardiovascular or metabolic disorders [12]. Notably, moderate to severe OSA increases the risk of severe cardiovascular events such as stroke, heart attack, and heart failure (HF) [13]. One of the ways OSA can cause CVD is by inducing inflammation in the body. Studies have shown that OSA can result in systemic and local inflammation in patients. This inflammation can trigger the impairment of vascular endothelial cells and further modify the structure and function of vessels, leading to endothelial dysfunction. Endothelial dysfunction is a key factor in the development of various end-organ morbidities, such as CVD and metabolic dysfunction [12]. Also, in individuals with type 2 diabetes mellitus (T2DM), OSA is associated with a higher risk of retinopathy, dementia, chronic kidney disease (CKD), and decreased renal function [14][15][16]. Moreover, recent studies have found that nearly half of the people with diabetes had OSA, with a bidirectional association between OSA and diabetes [17][18][19].

2. Cardiovascular Disease Outcomes Associated with Obstructive Sleep Apnea in Diabetics

OSA is a prevalent sleep disorder characterized by repeated upper airway obstruction during sleep. This results in reduced oxygen intake by the lungs, increased carbon dioxide levels in the body, and frequent sleep pattern disruptions. It has been hypothesized to elevate the risk of various CVDs, including stroke, in affected individuals [20]. Although the specific biological processes that underlie the association between CVD and OSA are not entirely understood, some mechanisms have been postulated, such as changes in chest pressure, heightened activity in the sympathetic nervous system, inflammation, and oxidative stress in blood vessels due to cycles of oxygen deprivation and restoration during sleep [20]. The sympathetic nervous system is hypothesized to be activated due to heightened sympathetic drive induced by repeated episodes of apnea and hypopnea, resulting in lower amounts of oxygen in the blood and increased carbon dioxide levels. Recurrent upper airway collapse during sleep, which results in the partial or total cessation of airflow despite continued respiratory effort, is a defining feature of OSA. This can increase respiratory effort against the blocked upper airway, leading to negative intrathoracic pressure. Research has suggested that OSA may be linked to higher levels of inflammatory cytokines and metabolic dysregulation, which may contribute to the development of atherosclerosis. However, due to the complex and diverse nature of OSA, the precise mechanisms that link it to CVD remain somewhat unclear [21].

The presence of diabetes with OSA enhances CVD risk. This is possible because OSA is associated with repetitive episodes of hypoxia–reoxygenation, triggering a cascade of metabolic and inflammatory changes that exacerbate pre-existing metabolic and cardiovascular risk factors in diabetes [11]. One potential mechanism involves insulin resistance, which is common in diabetes and known to promote inflammation and oxidative stress [22]. OSA is linked with impaired glucose metabolism and increased insulin resistance, leading to further inflammation, endothelial dysfunction, and the development of atherosclerosis and CVDs [23]. Another potential mechanism involves activating the renin–angiotensin–aldosterone system (RAAS), associated with maintaining blood pressure (BP). OSA activates the RAAS system, leading to an increase in BP and causing volume overload, contributing to the development of hypertension and CVDs [24]. Additionally, OSA is associated with increased sympathetic nervous system activity, which can further exacerbate hypertension and CVD risk in diabetes. Sympathetic activation can increase heart rate and vasoconstriction, leading to arrhythmias [25]. Overall, the mechanisms linking CVD and OSA in diabetics are likely multifactorial and involve a complex interplay between metabolic and inflammatory pathways.

Few studies explored the relationship with individual CVDs. For example, a cohort study conducted by Adderly et al. revealed that people with DM who developed OSA were at a greater risk of developing CVDs by over 50% [26]. Individuals with diabetes who developed OSA face a greater risk of peripheral neuropathy (PN), AF, diabetic foot disease (DFD), CKD, and all-cause mortality when compared with diabetics without OSA, even after adjusting for potential confounding factors [26]. This study also found that the newly diagnosed DM and OSA patients were at high risk of composite PN, DFD, CVD, and albuminuria [26]. However, the secondary analysis found no significant association between the individual factors of composite CKD, AF, CVD outcome, and all-cause death. The difference may be due to the shorter diabetes duration or better prevention in the OSA group before diabetes diagnosis. Similarly, another observational study found that individuals undergoing coronary artery bypass grafting (CABG) had a relatively higher prevalence of developing OSA and DM [27].The study also found that individuals with both OSA and DM had an elevated probability of emerging MACCEs and were more likely to be hospitalized for HF [27]. Findings further demonstrated that the presence of OSA and DM is independently related to the risk of MACCEs and hospitalization for HF following CABG, even after controlling for left ventricular ejection fraction and medication use [27]. However, it should be mentioned that the study had a few limitations, such as the possibility of unknown or unmeasured confounding variables, and the generalizability of the findings to emergency CABG or major non-cardiac-related surgeries may be limited. Also, the predominantly Asian study population had a limited representation of women subjects [27].

A prospective cohort study by Wang et al. demonstrated a link between OSA and DM, where patients with both conditions were at greater risk of MACCE following an ACS episode, compared to those with DM alone [28]. Interestingly, the prevalence of MACCE among non-DM patients was comparable between individuals with and without OSA. The high risk of adverse effects was mainly observed in patients with OSA and poor glucose control, which was further exacerbated in the presence of prolonged hypoxia, particularly if accompanied by DM [28]. A cross-sectional study by Rice et al. found a positive association between the apnea-hypopnea index (AHI) and stroke risk among obese individuals with type 2 DM, indicating that moderate and severe OSA can elevate the risk of stroke [29]. Notably, no significant association was observed between OSA and baseline CHD. These findings also suggest that identifying and addressing OSA may be crucial for mitigating stroke risk among obese individuals with DM [26][27][28][29].
These findings highlight the importance of considering the link between OSA and diabetes and not overlooking its potential impact on the occurrence of cardiovascular diseases. It is crucial to suggest regular screening for CVDs in patients with both OSA and diabetes to catch any issues early and manage them appropriately. Clinicians need to stay vigilant and well-informed about the potential effects of OSA when it coexists with diabetes, as it can lead to various negative cardiovascular outcomes. However, more research is needed to strengthen our understanding of this connection and how it affects clinical practice.
In conclusion, these studies emphasize the significance of acknowledging the association between OSA and diabetes and its potential influence on CVDs. Clinicians must remain vigilant and informed about the possible cardiovascular risks when OSA coexists with diabetes. The early detection and treatment of OSA in patients with diabetes may lower healthcare utilization and CVD risk in this population. The results of the studis emphasize the necessity for future research to gain a more comprehensive understanding of the intricate connection between OSA, diabetes, and CVD, thereby establishing efficient interventions for the prevention and management of these conditions in clinical practice.

References

  1. Lin, X.; Xu, Y.; Pan, X.; Xu, J.; Ding, Y.; Sun, X.; Song, X.; Ren, Y.; Shan, P.-F. Global, regional, and national burden and trend of diabetes in 195 countries and territories: An analysis from 1990 to 2025. Sci. Rep. 2020, 10, 14790.
  2. Rawshani, A.; Rawshani, A.; Franzén, S.; Eliasson, B.; Svensson, A.-M.; Miftaraj, M.; McGuire, D.K.; Sattar, N.; Rosengren, A.; Gudbjornsdottir, S. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N. Engl. J. Med. 2017, 376, 1407–1418.
  3. Einarson, T.R.; Acs, A.; Ludwig, C.; Panton, U.H. Prevalence of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc. Diabetol. 2018, 17, 83.
  4. Davies, M.J.; D’Alessio, D.A.; Fradkin, J.; Kernan, W.N.; Methieu, C.; Mingrone, G.; Rossing, P.; Tsapas, A.; Wexler, D.J.; Buse, J.B. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018, 41, 2669–2701.
  5. Senaratna, C.V.; Perret, J.L.; Lodge, C.J.; Lowe, A.J.; Campbell, B.E.; Matheson, M.C.; Hamilton, G.S.; Dharmage, S.C. Prevalence of obstructive sleep apnea in the general population: A systematic review. Sleep Med. Rev. 2017, 34, 70–81.
  6. Thompson, C.; Legault, J.; Moullec, G.; Baltzan, M.; Cross, N.; Dang-Vu, T.T.; Martineau-Dussault, M.-E.; Hanly, P.; Ayas, N.; Lorrain, D.; et al. A portrait of obstructive sleep apnea risk factors in 27,210 middle-aged and older adults in the Canadian Longitudinal Study on Aging. Sci. Rep. 2022, 12, 5127.
  7. Benjafield, A.V.; Ayas, N.T.; Eastwood, P.R.; Heinzer, R.; Ip, M.S.M.; Morell, M.J.; Nunez, C.M.; Patel, S.R.; Penzel, T.; Pepin, J.-L.; et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: A literature-based analysis. Lancet Respir. Med. 2019, 7, 687–698.
  8. Young, T.; Peppard, P.E.; Gottlieb, D.J. Epidemiology of obstructive sleep apnea: A population health perspective. Am. J. Respir. Crit. Care Med. 2002, 165, 1217–1239.
  9. Phillipson, E.A. Sleep apnea–A major public health problem. Mass Med. Soc 1993, 328, 1271–1273.
  10. White, D.P.; Younes, M.K. Obstructive sleep apnea. Compr. Physiol. 2012, 2, 2541–2594.
  11. Labarca, G.; Gower, J.; Lamperti, L.; Dreyse, J.; Jorquera, J. Chronic intermittent hypoxia in obstructive sleep apnea: A narrative review from pathophysiological pathways to a precision clinical approach. Sleep Breath. 2020, 24, 751–760.
  12. Unnikrishnan, D.; Jun, J.; Polotsky, V. Inflammation in sleep apnea: An update. Rev. Endocr. Metab. Disord. 2015, 16, 25–34.
  13. Marin, J.M.; Carrizo, S.J.; Vicente, E.; Agusti, A.G. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: An observational study. Lancet 2005, 365, 1046–1053.
  14. Tahrani, A.A. Obstructive sleep apnoea in diabetes: Does it matter? Diabetes Vasc. Dis. Res. 2017, 14, 454–462.
  15. Altaf, Q.A.; Dodson, P.; Ali, A.; Raymond, N.T.; Wharton, H.; Fellows, H.; Hampshire-Bancroft, R.; Shah, M.; Shepherd, E.; Miah, J.; et al. Obstructive sleep apnea and retinopathy in patients with type 2 diabetes. A longitudinal study. Am. J. Respir. Crit. Care Med. 2017, 196, 892–900.
  16. Sharma, S.; Behl, T.; Sehgal, A.; Singh, S.; Sharma, N.; Bhatia, S.; Al-Harassi, A.; Bungau, S.; Mostafavi, E. Possible role of Wnt signaling pathway in diabetic retinopathy. Curr. Drug Targets 2022, 23, 1372–1380.
  17. Qie, R.; Zhang, D.; Liu, L.; Ren, Y.; Zhao, Y.; Liu, D.; Liu, F.; Chen, X.; Cheng, C.; Guo, C.; et al. Obstructive sleep apnea and risk of type 2 diabetes mellitus: A systematic review and dose-response meta-analysis of cohort studies. J. Diabetes 2020, 12, 455–464.
  18. Fallahi, A.; Jamil, D.I.; Karimi, E.B.; Baghi, V.; Gheshlagh, R.G. Prevalence of obstructive sleep apnea in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab. Syndr. Clin. Res. Rev. 2019, 13, 2463–2468.
  19. Huang, T.; Lin, B.M.; Stampfer, M.J.; Tworoger, S.S.; Hu, F.B.; Redline, S. A population-based study of the bidirectional association between obstructive sleep apnea and type 2 diabetes in three prospective US cohorts. Diabetes Care 2018, 41, 2111–2119.
  20. Jean-Louis, G.; Zizi, F.; Brown, D.; Ogedegbe, G.; Borer, J.; McFarlane, S. Obstructive sleep apnea and cardiovascular disease: Evidence and underlying mechanisms. Minerva Pneumol. 2009, 48, 277.
  21. Bauters, F.; Rietzschel, E.R.; Hertegonne, K.B.; Chirinos, J.A. The link between obstructive sleep apnea and cardiovascular disease. Curr. Atheroscler. Rep. 2016, 18, 1.
  22. Tasali, E.; Ip, M.S. Obstructive sleep apnea and metabolic syndrome: Alterations in glucose metabolism and inflammation. Proc. Am. Thorac. Soc. 2008, 5, 207–217.
  23. Zhang, Y.; Xing, Y.; Yuan, H.; Gang, X.; Guo, W.; Li, Z.; Wang, G. Impaired glucose metabolisms of patients with obstructive sleep apnea and type 2 diabetes. J. Diabetes Res. 2018, 2018, 6714392.
  24. Torres, G.; Sánchez-de-la-Torre, M.; Barbé, F. Relationship between OSA and hypertension. Chest 2015, 148, 824–832.
  25. Somers, V.K.; Dyken, M.E.; Clary, M.P.; Abboud, F.M. Sympathetic neural mechanisms in obstructive sleep apnea. J. Clin. Investig. 1995, 96, 1897–1904.
  26. Adderley, N.J.; Subramanian, A.; Toulis, K.; Gokhale, K.; Taverner, T.; Hanif, W.; Haroon, S.; Thomas, G.N.; Sainsbury, C.; Tahrani, A.A.; et al. Obstructive sleep apnea, a risk factor for cardiovascular and microvascular disease in patients with type 2 diabetes: Findings from a population-based cohort study. Diabetes Care 2020, 43, 1868–1877.
  27. Aung, A.-T.; Koo, C.-Y.; Tam, W.W.; Chen, Z.; Kristanto, W.; Sim, H.-W.; Kojodjojo, P.; Kofidis, T.; Lee, C.-H. Sleep apnea and diabetes mellitus are independently associated with cardiovascular events and hospitalization for heart failure after coronary artery bypass grafting. Sci. Rep. 2020, 10, 21664.
  28. Wang, X.; Fan, J.; Du, Y.; Ma, C.; Ma, X.; Nie, S.; Wei, Y. Clinical significance of obstructive sleep apnea in patients with acute coronary syndrome in relation to diabetes status. BMJ Open Diabetes Res. Care 2019, 7, e000737.
  29. Rice, T.B.; Foster, G.D.; Sanders, M.H.; Unruh, M.; Reboussian, D.; Kuna, S.T.; Millman, R.; Zammit, G.; Wing, R.R.; Wadden, T.A.; et al. The relationship between obstructive sleep apnea and self-reported stroke or coronary heart disease in overweight and obese adults with type 2 diabetes mellitus. Sleep 2012, 35, 1293.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Cardiac & Cardiovascular Systems
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Ganesh Bushi
,
Bijaya Kumar Padhi
,
Muhammed Shabil
,
Prakasini Satapathy
,
Sarvesh Rustagi
,
Keerti Bhusan Pradhan
,
Zahraa Haleem Al-qaim
,
Jagdish Khubchandani
,
Ranjit Sah
,
Sanjit Sah
,
Ayush Anand
View Times: 317
Revisions: 2 times (View History)
Update Date: 22 Sep 2023
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback